Maclachlan, Kylee H. http://orcid.org/0000-0001-7873-4854
Rustad, Even H.
Derkach, Andriy http://orcid.org/0000-0003-2178-8493
Zheng-Lin, Binbin
Yellapantula, Venkata
Diamond, Benjamin http://orcid.org/0000-0002-8638-9365
Hultcrantz, Malin http://orcid.org/0000-0002-9045-6495
Ziccheddu, Bachisio
Boyle, Eileen M.
Blaney, Patrick
Bolli, Niccolò
Zhang, Yanming
Dogan, Ahmet http://orcid.org/0000-0001-6576-5256
Lesokhin, Alexander M.
Morgan, Gareth J. http://orcid.org/0000-0002-4271-6360
Landgren, Ola http://orcid.org/0000-0001-6485-4839
Maura, Francesco http://orcid.org/0000-0002-5017-1620
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (P30 CA 240139)
Article History
Received: 6 December 2020
Accepted: 2 August 2021
First Online: 27 August 2021
Competing interests
: O.L. has received research funding from: National Institutes of Health (NIH), National Cancer Institute (NCI), U.S. Food and Drug Administration (FDA), Multiple Myeloma Research Foundation (MMRF), International Myeloma Foundation (IMF), Leukemia and Lymphoma Society (LLS), Perelman Family Foundation, Rising Tide Foundation, Amgen, Celgene, Janssen, Takeda, Glenmark, Seattle Genetics, Karyopharm; Honoraria/ad boards: Adaptive, Amgen, Binding Site, BMS, Celgene, Cellectis, Glenmark, Janssen, Juno, Pfizer; and serves on Independent Data Monitoring Committees (IDMCs) for clinical trials lead by Takeda, Merck, Janssen, Theradex. All other authors have no conflicts of interest to declare.